FDA advisors back Cidara antifungal rezafungin

  26 January 2023

An FDA advisory committee has recommended approval of Cidara Therapeutics’ once-weekly antifungal therapy rezafungin, setting it up to become the first new option for severe infections caused by Candida species in a decade.

The panel voted 14 to 1 that the benefits of Cidara and Melinta Therapeutics’ once-weekly echinocandin drug outweighed its risks as a first-line treatment for candidemia and invasive candidiasis in adults who have limited or no alternative treatment options.

The decision puts Cidara and Melinta on course for a positive outcome when the FDA delivers its verdict on the filing, which is due by 22 March. If approved it will be sold by Melinta, which licensed US rights to it last July and already markets a range of antibacterial drugs.

Further reading: Pharmaphorum
Author(s): Phil Taylor
Healthy Patients  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!